| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | EUS-Guided Versus Percutaneous Transhepatic Drainage of Liver Abscesses: A Multicenter Endohepatology Study in Western Japan (EPIC-LA Study). |
| 掲載誌名 | 正式名：Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 略 称：Dig Endosc ISSNコード：14431661/09155635 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 38(1),pp.e70067 |
| 著者・共著者 | Takeshi Ogura, Taira Kuroda, Takanori Matsuura, Jun Kitadai, Koh Kitagawa, Masahiro Itonaga, Kotaro Takeshita, Tomoaki Matsumori, Tomoya Emori, Mamoru Takenaka, Hajime Imai, Koichiro Mandai, Shuhei Shinatani, Nao Fujimori, Hideyuki Shiomi, Masanori Asada, Ryota Sagami, Hirotsugu Maruyama, Tsukasa Ikeura, Masaaki Shimatani, Hidefumi Nishikiori, Kazuyuki Matsumoto, Masahito Kokubu, Hideki Kamada, Yusuke Ishida, Akitoshi Hakoda, Masayuki Kitano |
| 発行年月 | 2026/01 |
| 概要 | OBJECTIVE:Percutaneous transhepatic liver abscess drainage (PTAD) and endoscopic ultrasound-guided liver abscess drainage (EUS-LAD) have several limitations. Recently, because of technical improvements in echoendoscope maneuvers, EUS-guided access for the right hepatic lobe has been reported. The aim of this multicenter, retrospective study was to compare clinical outcomes of PTAD and EUS-LAD including the right hepatic lobe in West Japan.METHOD:This retrospective, multicenter study included consecutive patients with liver abscesses between January 2019 and November 2024. The primary outcome in this study was the clinical success rate compared between EUS-LAD and PTAD.RESULTS:During the study period, 1012 consecutive patients developed liver abscesses. Of them, 734 patients were excluded, 43 underwent EUS-LAD and 235 patients underwent PTAD. After propensity score-matched analysis, the clinical success rate was significantly higher in the EUS-LAD group (97.7%, 42/43) than in the PTAD group (79.1%, 34/43) (p = 0.007). After a propensity score-matched analysis, 25 patients were included in each group. The clinical success rate was significantly higher in the EUS-LAD group (100%, 25/25) than in the PTAD group (84%, 21/25) (p = 0.037). Adverse events were also significantly higher in the PTAD group (16%, 5/25) than in the EUS-LAD group (p = 0.025). In addition, the median length of hospital stay was significantly shorter in the EUS-LAD group (15 days) than in the PTAD group (22 days) (p = 0.005).CONCLUSIONS:EUS-LAD using a metal stent might be one of the options, but further randomized, controlled trials are needed. |
| DOI | 10.1111/den.70067 |
| PMID | 41307348 |